Human cytochrome P450 (CYP7B1) is a microsomal enzyme that utilizes NADPH-cytochrome P450 reductase as an electron donor and catalyzes $7\alpha$-hydroxylation of oxysterols [1]. CYP7B1 take part in several physiological functions depending on tissue localization, including bile acid biosynthesis [2], metabolism of steroid hormones (including neurosteroids) [3], regulation of immunoglobulin production [4] and metabolism of estrogen and androgen receptor ligands [5]. CYP7B1 dysfunctions are associated with a number of genetic disorders, such as liver failure in newborns neuropathy in adults. A list of point mutations in cyp7b1 gene was found to be connected with neurodegenerative disorder - spastic paraplegia type 5 (SPG5). But up to date it was unknown what happens with the product of the modified gene.
So in order to cast light on the molecular reason of the disease we decided to get recombinant mutant forms and to compare its with recombinant wild type (WT) enzyme. Application of site directed mutagenesis and molecular cloning allowed us to construct E. coli expression system for C57R, F216S and R486C mutants, that was found in patients with SPG5 as it was earlier reported [6]. When performing heterologous expression of the proteins we realized that C57R and F216S enzymes form inclusion bodies and can't be expressed in native form neither under the same condition as WT nor any other conditions. Expression level of R486C mutant was significantly lower, comparing WT, and was substantially enhanced when expressing at the presence of substrate (DHEA). Analyzing data on expression we put forward a hypothesis: R486 mutant has low conformational stability which leads to decrease of native enzyme level in biological tissues.In order to check hypothesis we applied several approaches, that allowed to compare conformational stability of R486C mutant and WT enzyme. We compared tolerance of the enzymes to chaotropic agents, such as urea, GuHCl, SDS and determine thermodynamic stability of the native form. It was demonstrated that energy barrier for folded-unfolded transition is lower for R486C mutant. Also we demonstrated that ligand-bound forms of both enzymes are more stable than ligand-free form. Fluorescence quenching experiments, aimed to follow tryptophan residues availability to different types of quenchers (cesium and iodine ions, acrylamide), showed that tryptophan residues are more accessible for a quencher exactly in R486C mutant. This observation is an indirect, but typical sign of stability and structure changes, driven by mutation.
In silico analysis, perfomed in our work, showed that R486C substitution leads to significant changes of the polypeptide backbone, including modification of the active site geometry.
So, the data obtained indicate that R486C replacement significantly reduce CYP7B1 conformational stability in model in vitro system and this alteration may be the reason of disorder induced by mutation, when considering in vivo system.